Inpatients with coronavirus disease 2019 (COVID-19) show a high rate of neuropsychiatric manifestations, possibly related to a higher risk of serious illness or death. Use of psychotropic medications (PMs) indicates the presence of neuropsychiatric symptoms in COVID-19 patients. So far, potential clinical predictors of use of PMs have not been much investigated. In order to extend research in this area, we aimed to investigate the prevalence of PM prescription among a sample of inpatients with COVID-19 and to find potential predictors of initiation of PMs in these individuals.

中文翻译：

---

COVID-19住院患者精神药物的启动：与临床和生物学特征的关联

2019 年冠状病毒病 (COVID-19) 住院患者的神经精神症状发生率很高，这可能与更高的严重疾病或死亡风险有关。精神药物 (PM) 的使用表明 COVID-19 患者存在神经精神症状。到目前为止，尚未对 PM 使用的潜在临床预测因素进行过多研究。为了扩展该领域的研究，我们旨在调查 COVID-19 住院患者样本中 PM 处方的流行情况，并找出这些个体开始 PM 的潜在预测因素。